Beckman Coulter introduces new integrated chemistry and immunoassay analyzer

Beckman Coulter Diagnostics, a clinical diagnostics leader, today introduces the new DxC 500i Clinical Analyzer*, an integrated clinical chemistry and immunoassay analyzer.

As healthcare systems around the world strategically adopt networked laboratory operational models for better efficiency and patient access, Beckman Coulter continues to introduce new innovations to address the needs of the entire network with specific solutions for satellite or independent laboratories, as well as core laboratories.

Utilizing Beckman Coulter’s common reagents and consumables across its scalable clinical chemistry and immunoassay portfolio, the DxC 500i Analyzer enables commutable patient results, offering hospitals and healthcare networks strategic benefits in patient care and inventory management.

“The development of the DxC 500i Analyzer is yet another example of how Beckman Coulter is investing in the needs of a broad range of laboratories across healthcare systems,” said Kathleen Orland, Senior Vice President, Business Unit, General Manager, Chemistry and Immunoassay for Beckman Coulter Diagnostics.

“The DxC 500i Clinical Analyzer powers both clinical chemistry and immunoassay testing in one space-saving package. With steadfast performance, practical simplicity, and trusted clinical quality, this analyzer meets the specific demands of the low-volume laboratory customer, standalone laboratories and community hospitals.”

The DxC 500i Clinical Analyzer features FlexMode operations, prioritizing immunoassay and chemistry testing according to each sample’s urgency. The new dynamic sample handler manages repeats and re-runs without operator intervention and pulls in a new sample rack as soon as the previous rack is offloaded, optimizing rapid throughput in a compact footprint.

Of equal importance, the DxC 500i’s intuitive interface supports even the newest users through proactive task indicators, step-by-step instructions and simplified staff onboarding and training.

In January, Beckman Coulter unveiled the DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyzer with onboard guided workflows, more than 120 assays, and standardized reagents for use across healthcare networks. The DxC 500i analyzer incorporates the DxC 500 AU technology within its clinical chemistry capabilities, including its Six Sigma performance.

The DxC 500i Clinical Analyzer is currently available in countries accepting CE mark.

Pending submission and clearance by the United States Food and Drug Administration, the analyzer is not yet available for in vitro diagnostic use in the U.S. Not all products are available in all countries. Product availability and regulatory status depends on country registration per applicable regulations.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news